← Back to Screener
Compugen Ltd (CGEN)
Price$2.19
Value ScoreB
Growth ScoreA
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)28.55%
Price vs S&P 500 (4W)-21.86%
VGM Score71.84
Market Capitalization$224.09M
P/E Ratio (Annual)6.34x
All Metrics
P/CF (Annual)7.08x
Book Value / Share (Quarterly)$1.09
P/TBV (Annual)0.73x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)113.28%
Cash Flow / Share (Quarterly)$0.33
Price vs S&P 500 (YTD)36.33%
Gross Margin (TTM)87.00%
Net Profit Margin (TTM)48.58%
EPS (TTM)$0.36
10-Day Avg Trading Volume0.59M
EPS Excl Extra (TTM)$0.36
Revenue Growth (5Y)105.20%
EPS (Annual)$0.38
ROI (Annual)34.40%
Gross Margin (Annual)94.01%
Net Profit Margin (5Y Avg)-443.04%
Cash / Share (Quarterly)$1.54
P/E Basic Excl Extra (TTM)6.34x
Revenue Growth QoQ (YoY)4480.41%
P/E Normalized (Annual)6.34x
ROA (Last FY)22.57%
Revenue Growth TTM (YoY)161.14%
EBITD / Share (TTM)$-0.40
ROE (5Y Avg)-41.50%
Operating Margin (TTM)43.05%
Cash Flow / Share (Annual)$0.33
P/B Ratio2.18x
P/B Ratio (Quarterly)1.39x
Net Income / Employee (Annual)$666,800
EV / Revenue (TTM)3.08x
Net Interest Coverage (TTM)0.50x
ROA (TTM)29.70%
EV / EBITDA (TTM)8.01x
EPS Incl Extra (Annual)$0.38
Current Ratio (Annual)6.56x
Quick Ratio (Quarterly)6.56x
3-Month Avg Trading Volume0.41M
52-Week Price Return50.67%
EV / Free Cash Flow (Annual)7.15x
P/E Incl Extra (TTM)6.34x
Revenue / Employee (TTM)$1,372,800
Tangible BV / Share (Quarterly)$0.60
P/S Ratio (Annual)6.70x
Asset Turnover (Annual)0.28x
52-Week High$3.23
Operating Margin (5Y Avg)-462.61%
EPS Excl Extra (Annual)$0.38
CapEx CAGR (5Y)4.81%
Tangible BV CAGR (5Y)21.53%
26-Week Price Return42.14%
Quick Ratio (Annual)6.47x
13-Week Price Return0.44%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.56x
Enterprise Value$224.09M
Revenue / Share Growth (5Y)98.61%
Asset Turnover (TTM)0.61x
Book Value / Share Growth (5Y)9.44%
Revenue / Employee (Annual)$631,300
Inventory Turnover (Annual)28.20x
Pretax Margin (Annual)-29.24%
Cash / Share (Annual)$1.54
3-Month Return Std Dev82.83%
Gross Margin (5Y Avg)91.74%
Net Income / Employee (TTM)$666,900
ROE (Last FY)34.40%
Net Interest Coverage (Annual)11.00x
EPS Basic Excl Extra (Annual)$0.38
P/FCF (TTM)5.28x
Receivables Turnover (TTM)2.68x
EV / Free Cash Flow (TTM)7.15x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$0.36
Receivables Turnover (Annual)29.70x
ROI (TTM)55.70%
P/S Ratio (TTM)3.08x
Pretax Margin (5Y Avg)-445.03%
Revenue / Share (Annual)$0.38
Tangible BV / Share (Annual)$0.90
Price vs S&P 500 (52W)22.51%
P/E Ratio (TTM)6.34x
EPS Growth TTM (YoY)20.54%
Year-to-Date Return47.71%
5-Day Price Return-18.12%
EPS Normalized (Annual)$0.38
ROA (5Y Avg)-33.24%
Net Profit Margin (Annual)-56.05%
Month-to-Date Return-14.07%
EBITD / Share (Annual)$0.34
Operating Margin (Annual)-38.83%
P/CF (TTM)7.08x
ROI (5Y Avg)-37.79%
P/E Excl Extra (TTM)6.34x
LT Debt / Equity (Quarterly)0.03x
EPS Basic Excl Extra (TTM)$0.36
P/TBV (Quarterly)1.06x
P/B Ratio (Annual)1.39x
Inventory Turnover (TTM)24.20x
Pretax Margin (TTM)48.65%
Book Value / Share (Annual)$1.09
Price vs S&P 500 (13W)-10.22%
Beta2.75x
P/FCF (Annual)7.15x
Revenue / Share (TTM)$0.76
ROE (TTM)55.70%
52-Week Low$1.29
vGradeB
gGradeA
mGradeC
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.08est. -0.07
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.36
4.36
4.36
4.33
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CGENCompugen Ltd | B | A | C | $2.19 |
| AMGNAmgen Inc | C | C | C | $338.22 |
| GILDGilead Sciences Inc | C | B | C | $128.99 |
| ARGXargenx SE American Depositary Shares | D | A | B | $813.14 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $155.99 |
| BIIBBiogen Inc. Common Stock | B | D | C | $195.96 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.45 |
| MRNAModerna, Inc. Common Stock | C | B | C | $49.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $165.11 |
| EXELExelixis Inc | C | B | B | $51.60 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $301.82 |
About
Compugen Ltd is a clinical-stage biopharmaceutical company developing cancer immunotherapies using computational drug discovery to identify novel immune targets. The company has four programs in clinical development targeting immune checkpoints and resistance pathways, including COM701, COM902, and bapotulimab, plus early-stage programs focusing on myeloid targets.